Tuesday, April 11, 2017


The emka & SCIREQ team will be attending the Experimental Biology 2017 conference in Chicago! We will present and demonstrate our wide range of preclinical instruments for neuro, pulmonary and cardio studies. Come by booth 315 and speak with our experienced team about our solutions for physiology, pharmacology and toxicology research.

A special focus on sleep studies with whole body plethysmography

Plethysmography utilizes a non-invasive technique which allows conscious polysomnography, or sleep studies, in unanaesthetized, spontaneously breathing subjects. This technique provides continuous high-fidelity respiratory recordings during sleep and wakefulness based on measures of tidal volume, respiratory rate and minute ventilation.

  • Easy-to-use, no surgery required
  • Does not require anaesthetics, which can depress the neural-network controlling respiration
  • Freely moving subjects, limiting stress-related changes in respiration due to restraints
  • Conscious, ability to respond to real-time changes
  • Plethysmography systems may also integrate with a mass flow controller to measure these respiratory effects under chronic intermittent periods of hypoxia, a key feature of sleep apnea.

Integration of electroencephalogram (EEG), electrocardiogram (ECG) & electromyogram (EMG) recordings with respiratory signals offer a detailed characterization of the neurological and cardiopulmonary contributions in a sleep-disordered breathing state.

  • Measures ventilatory parameters: Respiratory Rate (RR), estimated Tidal Volume (VT), Minute Ventilation (V) or Periodic breathing
  • Specific apnea analyzer for counting and analyzing apneas which can be precisely tuned for breath to breath acceptance or rejection
  • Automated alarms when clinically relevant physiologic triggers are reached
  • Gas mixture delivery (O2, CO2 and N2) can be automated through IOX software with protocols for evaluation of hypoxia, hyperoxia and hypercapnia.

easyTEL implantable system transmits physiological data from conscious freely moving laboratory animals. Our range of implants offers the ability to record the following parameters, depending on your study needs:
  • Biopotential (ECG, EEG, EMG)
  • Blood pressure
  • Temperature
  • Activity from acceleration

Click here to schedule a meeting with one of our specialists during EB 2017.
Exhibit Hours
Sunday, April 23rd - 9:00am to 4:00pm
Monday, April 24th - 9:00am to 4:00pm
Tuesday, April 25th - 9:00am to 4:00pm

Thursday, April 6, 2017

The End of an Era - retiring our legacy flexiVent System

Our legacy flexiVent system has officially retired starting March 1st, 2017.
The first legacy flexiVent system was introduced by SCIREQ in 1997 and some of these units are still being used to this day, almost 20 years later! During this time the flexiVent system has been used in pulmonary research applications, as an integral part of studies all over the globe, to generate accurate and consistent data related to lung mechanics.

Over the past few years it has become more difficult to support our legacy systems, with considerable rises in costs associated with maintenance and support for existing systems. After careful consideration, it was decided to retire the legacy flexiVent.
Should you come across issues when working with you flexiVent system, you may contact our technical support team at techsupport@scireq.com for assistance with acquiring relevant technical support documents which may assist you with troubleshooting the issue. However, as the legacy flexiVent system is no longer supported, it would not be possible to send the legacy components back to SCIREQ for repair. Further, due to limited resources in sourcing parts, replacement components are no longer available for purchase.
The updated flexiVent FX system was introduced in 2010.
We listened to your feedback and are pleased to inform you that in addition to including all the pre-existing features and capabilities of the legacy system, many significant improvements and features have been included into the flexiVent FX system. Some of the technical enhancements in the new flexiVent FX system include the use of field serviceable modules, significant reduction in noise during use, increased data accuracy as well as the possibility to now measure additional outcomes such as lung volumes.

Since being introduced, the flexiVent FX system has been used worldwide with constant improvements being made on the system by our development team which will further assist you in meeting your research goals.
If you are a legacy flexiVent system user and would like additional information regarding the new flexiVent FX new system, please feel free to contact us at sales@scireq.com or toll free at 1.877.572.4737. Our Application specialists would be happy to address any questions or concerns that you may have.

Thursday, March 9, 2017


The emka & SCIREQ team will be attending the 2017 Society of Toxicology conference in Baltimore. We will be demonstrating our wide range of preclinical instruments for neuro, pulmonary and cardio studies. Come by booth #1622 and speak with our experts about our solutions for physiology, pharmacology and toxicology research.

Come see our new E-cigarette exposure solution!

E-cigarette vapour composition is influenced by a number of factors, some relating to the device physically (battery charge, wattage/temperature control, puffing profile) and others relating to the e-liquid (proportion of propylene glycol and glycerol, amount of nicotine, pH of solution). Standardizing how we study E-cigarettes will be key to understanding their impact. 


Our E-cigarette extension offers:
»       Automated programmable puffing profiles for repeatability between studies and across laboratories.
»       Adapted power supply for stable voltage output and coil resistance providing consistent vapour generation.
»       Wattage and temperature control to maintain precise vapour density.
»       Large E-liquid tank for longer duration exposures.
»       Accessible tank for easy top-up to maintain level of E-liquid and avoid undesired decomposition.
Exhibit Hours
Monday, March 13th - 9:15am to 4:30pm
Tuesday, March 14th - 9:15am to 4:30pm
Wednesday, March 15th - 9:15am to 4:30pm

Click here to schedule a meeting with one of our experts during SOT 2017.

Thursday, February 2, 2017

Asthma - from mouse to man

“The assessment of lung function endpoints used in preclinical drug testing may hold the key to translation of drug efficacy from mouse to man1.”

Mouse models have been and continue to be of invaluable importance in asthma research, for the elucidation of key disease pathways as well as in the assessment of potential therapies2. While therapeutic candidates showing promise in murine models have not always translated into clinical successes, the story behind the recent FDA-approved anti-IL-5 and anti-IL-13 therapies3, previously deemed ineffective in general asthmatic populations, is a compelling example of how a better understanding of both the underlying disease mechanisms and the models resulted into “bench-to-bedside” achievements.

Mouse models of asthma
Asthma is a complex heterogeneous disease whose features have not been completely depicted by any single mouse disease model.  In preclinical (in vivo) research, careful considerations should be given to the model employed, its phenotype, as well as the measured outcomes.  Ideally, studies should include outcomes with strong predictive or translational value such as lung function measurements.  Respiratory function outcomes are often considered as primary study endpoint in many clinical trials targeting asthma patients. Therefore, relying on robust lung function measurements early on in the preclinical validation and development of potential disease targets and therapeutic candidates can, not only avoid misleading assessments, but also provide a grounded approach to support the critical program decision-making process.

Lung function outcomes
Lung function outcomes provided by SCIREQ‘s flexiVent and plethysmography methodologies aim to bridge the gap between mouse and man.  Referenced in thousands of peer-reviewed scientific publications and patents4, our scientific instruments permit accurate and detailed measurements to complement and strengthen biochemistry or immunology data.  These measurements are conveniently combined into a robust and comprehensive pulmonary assessment, collected via a computer-controlled instrument that also maximizes reproducibility.

Future direction
Mouse models represent a highly valuable tool to study the mechanisms involved in asthma and extrapolate scientific discoveries to humans.  The translatability of the information provided will only be ensured in the future by the continuous refinement of the models employed, as well as by a holistic approach combining lung mechanics data to a comprehensive assessment of the model phenotype.  This rigorous approach will hopefully help identify target populations and lead to additional success stories in the clinic, benefiting asthma patients worldwide.

Relevant links:

Tuesday, January 17, 2017

Together for Respiratory Research

January 15 to 21st is National Non-Smoking Week (NNSW) in Canada and we would like to take this opportunity to highlight the efforts of researchers, here and around the world, to deepen our knowledge on the health effects of smoke. Their work builds the scientific evidence to guide today’s and tomorrow’s decisions on the use of tobacco and tobacco-related products.  At SCIREQ, we understand respiratory research and take pride in assisting researchers in their task by providing precision laboratory instruments that enable them to achieve their scientific goals.

We believe that together we can make a difference.  

Read more

Monday, January 9, 2017

flexiVent featured in recent Nature publication

Congratulations to Dr. Ravichandran’s1 team at the University of Virginia, who recently published in Nature!

Their publication found that during phagocytosis, macrophages release insulin-like growth factor 1 (IGF-1) and microvesicles. Once bound to its receptor, IGF-1 promotes uptake of these microvesicles by the epithelial cells, leading to a decreased inflammatory response. This was verified through classic airway hyperresponsiveness (AHR) markers including increased eosinophils in the BAL fluid and increased airway resistance after methacholine challenges.
In vivo AHR was assessed using the flexiVent to both deliver aerosol challenges to the subject’s lungs and follow the developing bronchoconstriction through automated data collection. The data generated can be further partitioned to describe the contribution from the central airways and tissues, which often offers additional insight into the mechanisms and disease.

To learn more and read the full publication, visit Nature’s website at

To learn more about the flexiVent and how it may provide insight into inflammatory diseases or other applications, please contact info@scireq.com


1Ravichandran KS et al. Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation. Nature. 2016 Nov 24;539(7630):570-574. doi: 10.1038/nature20141. Epub 2016 Nov 7.

Thursday, December 8, 2016



emka TECHNOLOGIES S.A.S. (Paris, France)
Closed from Monday, December 26th to Friday, December 30th.

emka TECHNOLOGIES Inc. (Falls Church, VA, U.S.A.)
Closed on Monday, December 26th to Monday, January 2nd only. Open all other days.

SCIREQ Scientific Respiratory Equipment Inc. (Montreal, QC, Canada)
Closed from Monday, December 26th to Monday, January 2nd.